JP2015512447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512447A5 JP2015512447A5 JP2015504647A JP2015504647A JP2015512447A5 JP 2015512447 A5 JP2015512447 A5 JP 2015512447A5 JP 2015504647 A JP2015504647 A JP 2015504647A JP 2015504647 A JP2015504647 A JP 2015504647A JP 2015512447 A5 JP2015512447 A5 JP 2015512447A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine kinase
- inhibitor
- fgfr
- pharmaceutically acceptable
- met
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261619502P | 2012-04-03 | 2012-04-03 | |
| US61/619,502 | 2012-04-03 | ||
| PCT/US2013/034759 WO2013151913A1 (en) | 2012-04-03 | 2013-04-01 | Tyrosine kinase inhibitor combinations and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512447A JP2015512447A (ja) | 2015-04-27 |
| JP2015512447A5 true JP2015512447A5 (enExample) | 2016-05-19 |
Family
ID=48184451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504647A Pending JP2015512447A (ja) | 2012-04-03 | 2013-04-01 | チロシンキナーゼ阻害薬の組合せおよびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150051210A1 (enExample) |
| EP (1) | EP2833917A1 (enExample) |
| JP (1) | JP2015512447A (enExample) |
| KR (1) | KR20140146086A (enExample) |
| CN (1) | CN104244982A (enExample) |
| AU (1) | AU2013243737B2 (enExample) |
| CA (1) | CA2866321A1 (enExample) |
| IN (1) | IN2014DN07410A (enExample) |
| MX (1) | MX2014011987A (enExample) |
| RU (1) | RU2014143213A (enExample) |
| WO (1) | WO2013151913A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2715236C2 (ru) | 2014-03-26 | 2020-02-26 | Астекс Терапьютикс Лтд | Комбинации |
| CA2954862A1 (en) * | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
| EP3275442B1 (en) | 2015-03-25 | 2021-07-28 | National Cancer Center | Therapeutic agent for bile duct cancer |
| CN108367000A (zh) | 2015-12-17 | 2018-08-03 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| DE102005038537A1 (de) | 2005-08-16 | 2007-02-22 | Merck Patent Gmbh | 1-Acyldihydropyrazolderivate |
| HRP20170103T1 (hr) | 2005-12-21 | 2017-03-24 | Janssen Pharmaceutica N.V. | Triazolopiridazini kao modulatori tirozin kinaze |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| BRPI0717320A2 (pt) | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
| RS54510B1 (sr) * | 2006-11-22 | 2016-06-30 | Incyte Holdings Corporation | Imidazotriazini i imidazopirimidini kao inhibitori kinaze |
| JP4994044B2 (ja) * | 2007-01-05 | 2012-08-08 | シェブロンジャパン株式会社 | 潤滑油組成物 |
| AU2008239594B2 (en) * | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| TWI526687B (zh) * | 2008-04-29 | 2016-03-21 | 諾華公司 | 生物標記 |
| AU2009246263B2 (en) * | 2008-05-14 | 2014-08-21 | Amgen Inc. | Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| US20140057908A1 (en) * | 2010-09-27 | 2014-02-27 | Exelixis, Inc. | Method of Treating Cancer |
-
2013
- 2013-04-01 JP JP2015504647A patent/JP2015512447A/ja active Pending
- 2013-04-01 WO PCT/US2013/034759 patent/WO2013151913A1/en not_active Ceased
- 2013-04-01 RU RU2014143213A patent/RU2014143213A/ru not_active Application Discontinuation
- 2013-04-01 CA CA2866321A patent/CA2866321A1/en not_active Abandoned
- 2013-04-01 MX MX2014011987A patent/MX2014011987A/es unknown
- 2013-04-01 IN IN7410DEN2014 patent/IN2014DN07410A/en unknown
- 2013-04-01 KR KR1020147027542A patent/KR20140146086A/ko not_active Withdrawn
- 2013-04-01 CN CN201380018928.6A patent/CN104244982A/zh active Pending
- 2013-04-01 AU AU2013243737A patent/AU2013243737B2/en not_active Ceased
- 2013-04-01 US US14/388,251 patent/US20150051210A1/en not_active Abandoned
- 2013-04-01 EP EP13718671.4A patent/EP2833917A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8518930B2 (en) | Therapeutic combination comprising a CDKS inhibitor and an antineoplastic agent | |
| MX2024010140A (es) | Nuevos metodos. | |
| WO2015048662A3 (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| PH12013501594A1 (en) | Substituted indazole derivatives active as kinase inhibitors | |
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| JP2019516711A5 (enExample) | ||
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| EA201170249A1 (ru) | 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| JP2012236857A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| HRP20160562T1 (hr) | Derivat pirimidina kao inhibitori fak | |
| EA201490016A1 (ru) | Комбинация панобиностата и руксолитинаба при лечении рака, такого как миелопролиферативное новообразование | |
| HRP20190537T1 (hr) | Farmaceutske kombinacije koje sadrže inhibitor b-raf, inhibitor egfr i po izboru inhibitor pi3k-alfa | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| HRP20120918T1 (hr) | Aminopirazolski spoj | |
| GEAP202416013A (en) | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors | |
| ATE453646T1 (de) | 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| EA201290694A1 (ru) | Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы | |
| EA201270651A1 (ru) | Карбоксамиды пиридинон гидроксициклопентила: ингибиторы вич интегразы и области терапевтического применения | |
| JP2015512447A5 (enExample) |